eicosapentaenoic acid ethyl ester has been researched along with Chronic Kidney Failure in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yorioka, N | 1 |
| Masaki, T | 1 |
| Ito, T | 1 |
| Kushihata, S | 1 |
| Nishida, Y | 1 |
| Taniguchi, Y | 1 |
| Oda, H | 1 |
| Yamakido, M | 1 |
| Ando, M | 1 |
| Sanaka, T | 1 |
| Nihei, H | 1 |
1 trial available for eicosapentaenoic acid ethyl ester and Chronic Kidney Failure
| Article | Year |
|---|---|
Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients.
Topics: Administration, Oral; Adult; Aged; Arteriosclerosis; Drug Administration Schedule; Eicosapentaenoic | 1999 |
1 other study available for eicosapentaenoic acid ethyl ester and Chronic Kidney Failure
| Article | Year |
|---|---|
Lipid-lowering therapy and coagulation/fibrinolysis parameters in patients on peritoneal dialysis.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Coagulation Factors; Drug Therapy, Combination; Eicosap | 2000 |